From the perspective of the development history of China’s pharmaceutical intermediates industry, after nearly 30 years of development, pharmaceutical intermediates have developed from a small branch of the chemical industry into an emerging industry with an output value of billions of yuan, and its market competition has become increasingly fierce.

It is understood that in the early stage of the development of pharmaceutical intermediates industry, due to small investment and high return rate, pharmaceutical intermediates enterprises have mushroed like mushroom, especially in Zhejiang, Taizhou, Nanjing and other regions with favorable conditions for the development of pharmaceutical intermediates development is particularly rapid.

At present, as the change of medical market pattern, as well as the production of new drugs on the market is limited, the difficulty of pharmaceutical intermediates industry new product development is more and more big, the traditional product is becoming more and more fierce competition, pharmaceutical intermediates industry profits fell rapidly, and pharmaceutical intermediates become a have to think about the problem of how the development of an enterprise.

The industry believes that it may be possible to form its own competitive advantage from the aspects of technology, influence and transformation, so as to stand out in the market.

In terms of technology, it mainly refers to improving technology and saving cost.It is reported that the process route of pharmaceutical intermediate is long, reaction step is much, solvent usage is big, technical improvement potential is big.

For example, less valuable raw materials may be used instead of more valuable raw materials, such as liquid bromide in the production of aminothioamidic acid and ammonium thiocyanate in the production instead of potassium thiocyanate (sodium).

In addition, a single solvent can be used to replace the different solvents in the reaction process, and the alcohols generated from the hydrolysis of ester products can be recovered.

In terms of influence, it mainly forms its own characteristic products and improves its influence in the industry.It is understood that due to the serious product homogenization competition in China’s pharmaceutical intermediates industry, if enterprises can create their own advantageous products, they will definitely have more advantages in the market.

In terms of transformation, at present, with stricter environmental protection requirements in China, resources are inclined to high-value-added industries, and with the increase of environmental protection costs, transformation has become a problem that has to be considered for the sustainable development of pharmaceutical intermediates enterprises.

It is suggested that pharmaceutical intermediates enterprises should extend the industrial chain upstream and downstream, and turn the main raw materials they use into their own production. In this way, the cost can be further reduced, and for some special raw materials, the monopoly of key raw materials can be avoided.

The industry says a downward spiral, in which pharmaceutical intermediates are synthesized directly into apis, could further increase the added value of products while selling them directly to pharmaceutical companies.It is worth noting that there is a large investment in the downstream extension, as well as a high requirement for production technology and a good relationship with the API users.In general, leading enterprises will gain more competitive advantages.

In addition, RESEARCH and development is of great significance to the intermediate industry. Currently, China’s pharmaceutical intermediate industry generally pays less attention to research and development.Therefore, in the context of constantly improving technical requirements, efficient R&D enterprises with strong R&D strength will come to the fore, while small and medium-sized enterprises without r&d capability may be eliminated by the market. In the future, the industry concentration will be further improved and the middle and low-end development stage will be developed to a higher stage.